NEW YORK – Health data integrator and analytics firm Datavant announced on Thursday a partnership with Prognos, which includes the purchase of Prognos' deidentification technology.
San Francisco-based Datavant, launched in 2017 as a spinoff from drug company Roivant Sciences, takes over Opal, Prognos' back-end technology for deidentifying and linking data from diagnostic laboratories. Opal, which has been offered for free to Prognos analytics customers, serves as a security token to protect the identity of patients.
Datavant marketing chief Bob Borek told GenomeWeb that the company plans on migrating Opal users to Datavant's back-end technology over the second half of 2019. Opal will be discontinued, though Datavant will incorporate some elements of the Prognos technology into its own deidentification platform.
"We're trying to make [our security] token this anonymous ID, ubiquitous in healthcare," Borek said.
The deal will "bring major labs into the Datavant ecosystem," according to Borek. He said that Opal is well known among diagnostic labs but not among the pharmaceutical and biotechnology companies that use Prognos analytics tools.
New York-based Prognos applies artificial intelligence to clinical diagnostics and lab testing to predict disease.
Also as part of the partnership is a referral agreement, under which Prognos will be able to offer its analytics services to Datavant's clientele in pharma and biotech.
"Partnering with Datavant will be a force multiplier to Prognos' analytical capabilities by leveraging Datavant’s ecosystem to expand our existing data partnerships across data types," Prognos CEO and Cofounder Sundeep Bhan said in a statement. "Giving our customers a more comprehensive view of the patient will result in better and more forward-looking insights to improve decisionmaking."
Financial and other terms of the deal were not disclosed.